

Patient Information	l	Specimen Informa	tion	Client Information
DOB: Gender:	AGE:	Specimen: Requisition: Lab Ref #:		
Phone: Patient ID:		Collected: Received: Reported:		
COMMENTS.	FASTING:YES			
COMMENTS:	FASTING. TES			
Test Name		In Range	Out Of Range	Reference Range Lab
LIPID PANEL, CHOLESTEROI HDL CHOLES	L, TOTAL	150	38 L	<200 mg/dL >40 mg/dL
TRIGLYCERI			184 H	<150 mg/dL
LDL-CHOLES Referen	FEROL nce range: <100	84		mg/dL (calc)
<70 mg/	ole range <100 mg/dI 'dL for patients wit or = 2 CHD risk fac	h CHD or diabe		
better estimat Martin (http:/ CHOL/HDLC H NON HDL CHO For pat factor, (LDL-C option. COMPREHENSIV PANEL	DLESTEROL tients with diabetes treating to a non- of <70 mg/dL) is co	Triedewald equat 3;310(19): 2063 agnostics.com/fa 3.9 112 s plus 1 major A HDL-C goal of	tion in the 1-2068 aq/FAQ164) ASCVD risk <100 mg/dL rapeutic	<5.0 (calc) <130 mg/dL (calc)
GLUCOSE			102 H	65-99 mg/dL
			Fa	sting reference interval
	eone without known	diabetes, a glu is consistent o		
prediab	betes and should be up test.			
prediak follow- UREA NITROO	betes and should be up test.	confirmed with		7-25 mg/dL
prediak follow- UREA NITROC CREATININE	betes and should be oup test. GEN (BUN)	confirmed with 15 0.91		0.60-1.35 mg/dL
prediak follow- UREA NITRO CREATININE eGFR NON-AN	betes and should be rup test. GEN (BUN) FR. AMERICAN	confirmed with 15 0.91 111		0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2
prediab follow- UREA NITRO CREATININE eGFR NON-AN	betes and should be rup test. GEN (BUN) FR. AMERICAN AN AMERICAN	confirmed with 15 0.91	a	0.60-1.35 mg/dL
prediab follow- UREA NITRO CREATININE eGFR NON-AN eGFR AFRICA	betes and should be rup test. GEN (BUN) FR. AMERICAN AN AMERICAN	confirmed with 15 0.91 111 129 NOT APPLICA 140	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L
prediab follow- UREA NITRO CREATININE eGFR NON-AJ eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM	betes and should be rup test. GEN (BUN) FR. AMERICAN AN AMERICAN	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE	betes and should be rup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIO	betes and should be rup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE	betes and should be oup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIO CALCIUM	betes and should be oup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26 9.6 7.2 4.8	a	0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL 6.1-8.1 g/dL 3.6-5.1 g/dL
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIO CALCIUM PROTEIN, TO ALBUMIN GLOBULIN	betes and should be oup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO KIDE OTAL	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26 9.6 7.2 4.8 2.4	a	<pre>0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL 6.1-8.1 g/dL 3.6-5.1 g/dL 1.9-3.7 g/dL (calc)</pre>
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIO CALCIUM PROTEIN, TO ALBUMIN GLOBULIN ALBUMIN/GLO	Detes and should be Fup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO XIDE DTAL	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26 9.6 7.2 4.8 2.4 2.0	a	<pre>0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL 6.1-8.1 g/dL 3.6-5.1 g/dL 1.9-3.7 g/dL (calc) 1.0-2.5 (calc)</pre>
prediab follow- UREA NITRO CREATININE eGFR NON-AI eGFR AFRIC BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIO CALCIUM PROTEIN, TO ALBUMIN GLOBULIN ALBUMIN/GLO BILIRUBIN,	Detes and should be Fup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO XIDE DTAL DBULIN RATIO TOTAL	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26 9.6 7.2 4.8 2.4 2.0 0.4	a	<pre>0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL 6.1-8.1 g/dL 3.6-5.1 g/dL 1.9-3.7 g/dL (calc) 1.0-2.5 (calc) 0.2-1.2 mg/dL</pre>
prediab follow- UREA NITROC CREATININE eGFR NON-AI eGFR AFRICA BUN/CREATIN SODIUM POTASSIUM CHLORIDE CARBON DIOA CALCIUM PROTEIN, TO ALBUMIN GLOBULIN ALBUMIN/GLO	Detes and should be Fup test. GEN (BUN) FR. AMERICAN AN AMERICAN NINE RATIO XIDE DTAL DBULIN RATIO TOTAL	confirmed with 15 0.91 111 129 NOT APPLICA 140 4.2 105 26 9.6 7.2 4.8 2.4 2.0	a	<pre>0.60-1.35 mg/dL > OR = 60 mL/min/1.73m2 > OR = 60 mL/min/1.73m2 6-22 (calc) 135-146 mmol/L 3.5-5.3 mmol/L 98-110 mmol/L 20-32 mmol/L 8.6-10.3 mg/dL 6.1-8.1 g/dL 3.6-5.1 g/dL 1.9-3.7 g/dL (calc) 1.0-2.5 (calc)</pre>

SPECIMEN:



Patient Information	Specimen Informatio	n	Client Information	
	Specimen:			
	Collected:			
DOB: AGE:	Received:			
Gender:	Reported:			
Patient ID:				
Test Name	In Range	Out Of Range	Reference Range	Lab
CBC (INCLUDES DIFF/PLT)				
WHITE BLOOD CELL COUNT	6.4		3.8-10.8 Thousand/uL	
RED BLOOD CELL COUNT HEMOGLOBIN	4.98 15.0		4.20-5.80 Million/uL 13.2-17.1 g/dL	
HEMOGLOBIN HEMATOCRIT	42.1		38.5-50.0 %	
MCV	84.5		80.0-100.0 fL	
MCH	30.1		27.0-33.0 pg	
MCHC	35.6		32.0-36.0 g/dL	
RDW	12.3		11.0-15.0 %	
PLATELET COUNT	272		140-400 Thousand/uL	
MPV	9.8		7.5-12.5 fL	
ABSOLUTE NEUTROPHILS	4410		1500-7800 cells/uL	
ABSOLUTE LYMPHOCYTES ABSOLUTE MONOCYTES	1408 358		850-3900 cells/uL 200-950 cells/uL	
ABSOLUTE EOSINOPHILS	173		15-500 cells/uL	
ABSOLUTE BASOPHILS	51		0-200 cells/uL	
NEUTROPHILS	68.9		e	
LYMPHOCYTES	22.0		00	
MONOCYTES	5.6		₽ 	
EOSINOPHILS	2.7		8	
BASOPHILS	0.8		8	
URINALYSIS, COMPLETE COLOR	YELLOW		YELLOW	
APPEARANCE	CLEAR		CLEAR	
SPECIFIC GRAVITY	1.011		1.001-1.035	
PH	6.0		5.0-8.0	
GLUCOSE	NEGATIVE		NEGATIVE	
BILIRUBIN	NEGATIVE		NEGATIVE	
KETONES		TRACE	NEGATIVE	
OCCULT BLOOD	NEGATIVE		NEGATIVE	
PROTEIN NITRITE	NEGATIVE NEGATIVE		NEGATIVE NEGATIVE	
LEUKOCYTE ESTERASE	NEGATIVE		NEGATIVE	
WBC	NONE SEEN		< OR = 5 / HPF	
RBC	NONE SEEN		< OR = 2 / HPF	
SQUAMOUS EPITHELIAL CELL	S NONE SEEN		< OR = 5 /HPF	
BACTERIA	NONE SEEN		NONE SEEN /HPF	
HYALINE CAST	NONE SEEN		NONE SEEN /LPF	
DHEA SULFATE	457		106-464 mcg/dL	
PSA, TOTAL	1.1	4 ~	< OR = 4.0 ng/mL	
	from this assay system the WHO standard. The			
	ximately 20% lower whe			
	ndardized total PSA (B			
	of serial PSA results			
interpreted with this				
This test was perform	med using the Siemens			
	hod. Values obtained f	rom		
different assay metho				
	levels, regardless of			
	interpreted as absolu			
—	ence or absence of dis	ease.		
TESTOSTERONE, FREE				
(DIALYSIS) AND TOTAL, MS		245 L	250 - 1100 mc/dt	
TESTOSTERONE, TOTAL, MS		61J LI	250-1100 ng/dL	



Patient Information		Specimen Informa	tion	Client Information	
DOB: Gender: Patient ID:	AGE:	Specimen: Collected: Received: Reported:			
Test Name		In Range	Out Of Range I	Reference Range	Lab

Test Name TESTOSTERONE, FREE **In Range** Out Of Range Referent 59.7 35.0-15

Reference Range 35.0-155.0 pg/mL

**Data from J Clin Invest 1974:53:819-828 and J Clin Endocrinol Metab 1973;36:1132-1142. Men with clinically significant hypogonadal symptoms and testosterone values repeatedly in the range of the 200-300 ng/dL or less, may benefit from testosterone treatment after adequate risk and benefits counseling.

For additional information, please refer to http://education.questdiagnostics.com/faq/FAQ165 (This link is being provided for informational/ educational purposes only.)

This test was developed and its analytical performance characteristics have been determined by Quest Diagnostics Nichols Institute Valencia. It has not been cleared or approved by the US Food and Drug Administration. This assay has been validated pursuant to the CLIA regulations and is used for clinical purposes.



Patient Information	Specimen Information	Client Information
DOB: AGE: Gender: Patient ID:	Specimen: Collected: Received: Reported:	

Endocrinology

Test Name		Result	Reference Range	erence Range		
VITAMIN D,25-OH,TOTAL,IA		22 L	30-100 ng/mL			
Vitamin D Status	25-OH Vitamin D:					
Deficiency: Insufficiency:	<20 ng/mL 20 - 29 ng/mL					
Optimal:	> or = 30 ng/mL					

For 25-OH Vitamin D testing on patients on D2-supplementation and patients for whom quantitation of D2 and D3 fractions is required, the QuestAssureD(TM) 25-OH VIT D, (D2,D3), LC/MS/MS is recommended: order code 92888 (patients >2yrs).

For more information on this test, go to: http://education.questdiagnostics.com/faq/FAQ163 (This link is being provided for informational/ educational purposes only.)

Physician Comments:

PERFORMING SITE: